Scheinberg Lab
Principal Investigator: David A Scheinberg
Institution: Memorial Sloan Kettering Cancer Center (New York, NY)
Primary Subfield: Molecular & Cell Bio
Recruitment Status: ✅ Hiring Postdocs
Research Focus
Abstract The goals of my research since 1978 have been to distinguish the features of cancer cells from healthy cells in order to be able to discover and develop safe and selective, innovative immunotherapies. Here, we leverage my past body of work that has evolved from native mouse antibodies, to humanized mAb, to various potent conjugates of these mAb, to TCRm antibodies, and ultimately to BiTE forms and CAR forms to create the latest generation of agents and experiments now proposed. This scientific progression has been sustained for more than 3 decades. This work is innovative, as noted by our numerous therapeutic firsts and more than 3 dozen patents, including: human antibodies for the treatment of acute leukemia, targeted alpha- particle therapies, in vivo alpha-particle isotope generators, oncogenic fusion point vaccines, human TCR mimic antibodies to intracellular oncogenic proteins, and most recently, various innovative CAR technologies, now in progress. Several of the antibodies and vaccines reached late stage, national clinical trials such as a WT1 vaccine, Galenpepimut, and our alpha generator-Lintuzumab. But now, how do we achieve true cancer specificity? The immune sy…
Active NIH Awards
- 5R35CA241894-07: Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies. (2026)
- 5R35CA241894-06: Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies. (2025)
- 5R35CA241894-05: Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies. (2024)
Explore 700+ US Biology Labs on FindBioLabs.com